Julie Sommet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Julie Sommet has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
André Baruchel
Hôpital Robert-Debré, Service d'Hématologie, AP-HP, Paris, France
1 shared publicationAndré Denjean
Hôpital Robert-Debré, Service de Physiologie, AP-HP, Paris, France
1 shared publicationCorinne Alberti
U 1123, ECEVE, Hôpital Robert-Debré, INSERM, Paris, France
1 shared publicationDamir Mohamed
Hôpital Robert-Debré, Unité d'Epidémiologie Clinique, AP-HP, Paris, France
1 shared publicationFlorence Missud
Hôpital Robert-Debré, Service d'Hématologie, AP-HP, Paris, France
1 shared publicationGhislaine Ithier
Hôpital Robert-Debré, Service d'Hématologie, AP-HP, Paris, France
1 shared publication
Latest Publications
- Open Access
- 5 January 2016
- Published by Wiley in British Journal of Haematology
- Vol. 172 (6) , 966-977
Clinical and haematological risk factors for cerebral macrovasculopathy in a sickle cell disease newborn cohort: a prospective study
Summary: Children with sickle cell disease (SCD) have a significant vascular morbidity, especially cerebral macrovasculopathy (CV), detectable by transcranial Doppler. This study aimed to identify risk factors for CV using longitudinal biological and clinical data in a SCD newborn cohort followed at the Robert Debre Reference centre (n = 375 SS/Sβ0). Median follow‐up was 6·8 years (2677 patient‐years). Among the 59 children presenting with CV, seven had a stroke. Overall, the incidence of CV was 2·20/100 patient‐years [95% confidence interval (95%CI): 1·64–2·76] and the incidence of stroke was 0·26/100 patient‐years (95%CI: 0·07–0·46). The cumulative risk of CV by age 14 years was 26·0% (95%CI: 20·0‐33·3%). Risk factors for CV were assessed by a Cox model encompassing linear multivariate modelling of longitudinal quantitative variables. Years per upper‐airway obstruction [Hazard ratio (HR) = 1·47; 95%CI: 1·05–2·06] or bronchial obstruction (HR = 1·76; 95% CI: 1·49–2·08) and reticulocyte count (HR = 1·82 per 50 × 109/l increase; 95%CI: 1·10–3·01) were independent risk factors whereas fetal haemoglobin level (HR = 0·68 per 5% increase; 95%CI: 0·48–0·96) was protective. Alpha‐thalassaemia was not protective in multivariate analysis (ancillary analysis n = 209). Specific treatment for upper or lower‐airway obstruction and indirect targeting of fetal haemoglobin and reticulocyte count by hydroxycarbamide could potentially reduce the risk of CV.
- 5 January 2016
- Published by Wiley in British Journal of Haematology
- Vol. 172 (6) , 966-977
Open AccessClinical and haematological risk factors for cerebral macrovasculopathy in a sickle cell disease newborn cohort: a prospective study
Summary: Children with sickle cell disease (SCD) have a significant vascular morbidity, especially cerebral macrovasculopathy (CV), detectable by transcranial Doppler. This study aimed to identify risk factors for CV using longitudinal biological and clinical data in a SCD newborn cohort followed at the Robert Debre Reference centre (n = 375 SS/Sβ0). Median follow‐up was 6·8 years (2677 patient‐years). Among the 59 children presenting with CV, seven had a stroke. Overall, the incidence of CV was 2·20/100 patient‐years [95% confidence interval (95%CI): 1·64–2·76] and the incidence of stroke was 0·26/100 patient‐years (95%CI: 0·07–0·46). The cumulative risk of CV by age 14 years was 26·0% (95%CI: 20·0‐33·3%). Risk factors for CV were assessed by a Cox model encompassing linear multivariate modelling of longitudinal quantitative variables. Years per upper‐airway obstruction [Hazard ratio (HR) = 1·47; 95%CI: 1·05–2·06] or bronchial obstruction (HR = 1·76; 95% CI: 1·49–2·08) and reticulocyte count (HR = 1·82 per 50 × 109/l increase; 95%CI: 1·10–3·01) were independent risk factors whereas fetal haemoglobin level (HR = 0·68 per 5% increase; 95%CI: 0·48–0·96) was protective. Alpha‐thalassaemia was not protective in multivariate analysis (ancillary analysis n = 209). Specific treatment for upper or lower‐airway obstruction and indirect targeting of fetal haemoglobin and reticulocyte count by hydroxycarbamide could potentially reduce the risk of CV.